The MSH6 Gene Mismatch Repair Cancer Syndrome Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify mutations in the MSH6 gene that are associated with an increased risk of developing various types of cancer, most notably Lynch syndrome. Lynch syndrome is a hereditary condition that significantly raises the risk of colorectal cancer, endometrial cancer, and several other forms of cancer at an early age. The MSH6 gene plays a crucial role in the DNA mismatch repair system, which corrects errors that occur during DNA replication. Mutations in this gene can disrupt the repair process, leading to an accumulation of DNA errors and, consequently, an increased likelihood of cancer development.
The test is priced at 4400 AED and involves collecting a DNA sample, usually through a blood draw or cheek swab, which is then analyzed in the laboratory to detect any abnormalities in the MSH6 gene. This genetic test is particularly recommended for individuals with a family history of Lynch syndrome or related cancers, as it can provide crucial information for making informed decisions about cancer surveillance and preventive measures. Early detection of a predisposition to cancer can lead to timely interventions, significantly reducing the risk of developing cancer or detecting it at an early, more treatable stage.
The PMS2 Gene Mismatch Repair Cancer Syndrome Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify mutations in the PMS2 gene that are associated with a higher risk of developing certain types of cancer. This gene plays a crucial role in the DNA mismatch repair system, which helps maintain the integrity of the genetic material in cells. Mutations in the PMS2 gene can lead to a condition known as Lynch syndrome or hereditary non-polyposis colorectal cancer (HNPCC), which significantly increases the risk of developing colorectal cancer, endometrial cancer, and several other types of cancer at a younger age than typically observed in the general population.
The test, priced at 4400 AED, involves analyzing the individual's DNA to detect any abnormalities in the PMS2 gene. It is recommended for individuals with a family history of Lynch syndrome-associated cancers or those who have personal history suggestive of the syndrome. By identifying mutations early, the test enables proactive management and surveillance strategies for affected individuals and their families, potentially reducing the risk of cancer development or facilitating early detection and treatment.
DNA Labs UAE employs state-of-the-art genetic testing technologies to ensure accurate and reliable results, providing a crucial tool in the fight against hereditary cancer syndromes.
The "KRAS Gene Leukemia Acute Myelogenous Genetic Test" is a sophisticated diagnostic tool offered by DNA Labs UAE, designed to detect mutations in the KRAS gene, which are often implicated in the development of Acute Myelogenous Leukemia (AML), a type of cancer that affects the blood and bone marrow. This test plays a crucial role in the diagnosis, prognosis, and management of AML by providing vital genetic information that can guide treatment decisions, including targeted therapy options. The cost of the test is 4400 AED, reflecting the advanced technology and expertise required to analyze genetic mutations with precision. By identifying specific genetic alterations in the KRAS gene, healthcare providers can tailor treatment plans to the individual patient, potentially improving outcomes and reducing the risk of adverse effects.
The "KIT Gene Leukemia Acute Myeloid Genetic Test" is a specialized diagnostic procedure available at DNA Labs UAE, designed to identify mutations in the KIT gene that are often associated with acute myeloid leukemia (AML). This genetic test plays a critical role in the diagnosis and management of AML, as mutations in the KIT gene can influence the disease's prognosis and guide treatment strategies. By analyzing a patient's DNA sample, the test can detect specific genetic alterations in the KIT gene, helping healthcare providers to tailor more effective treatment plans based on the genetic makeup of the leukemia. The test is priced at 4400 AED and is conducted in the state-of-the-art facilities of DNA Labs UAE, ensuring high accuracy and reliability of the results.
The RUNX1 Gene Leukemia Acute Myeloid Genetic Test is a specialized diagnostic tool available at DNA Labs UAE, designed to detect mutations in the RUNX1 gene, which are often associated with an increased risk of developing acute myeloid leukemia (AML). This genetic test plays a crucial role in the early detection and management of AML, enabling healthcare providers to devise personalized treatment plans based on the genetic makeup of an individual's leukemia. Priced at 4400 AED, the test involves analyzing the patient's DNA to identify specific alterations in the RUNX1 gene that could predispose them to AML, thereby facilitating early intervention and potentially improving treatment outcomes.
The "CEBPA Gene Leukemia Acute Myeloid Somatic Genetic Test" is a specialized diagnostic procedure aimed at identifying mutations in the CEBPA gene, which are associated with acute myeloid leukemia (AML). This gene plays a crucial role in the development and function of white blood cells, and mutations can lead to uncontrolled cell growth, a hallmark of leukemia. The test is particularly significant for patients diagnosed with AML, as the presence of CEBPA mutations can influence treatment decisions and prognosis.
Performed at DNA Labs UAE, a leading facility in genetic diagnostics, the test involves analyzing the patient's DNA to detect abnormalities in the CEBPA gene. It's a sophisticated process that requires a sample of the patient's blood or bone marrow. Given the complexity and the precision of the technology used, the cost of the test is 4400 AED. Identifying CEBPA mutations can help clinicians tailor treatment strategies more effectively, potentially improving patient outcomes. This test is an invaluable tool in the personalized medicine approach to treating acute myeloid leukemia.
The ZBTB16 Gene Leukemia Acute Promyelocytic PLZF/RARA Type Genetic Test is a sophisticated diagnostic procedure aimed at identifying the specific genetic mutation associated with a subtype of acute promyelocytic leukemia (APL). This particular type of leukemia, characterized by the fusion of the ZBTB16 (also known as PLZF) gene and the RARA gene, results in a unique clinical presentation and requires targeted treatment strategies. The test is crucial for the accurate diagnosis and management of patients, guiding therapeutic decisions that are tailored to the genetic profile of the leukemia.
Performed at DNA Labs UAE, a leading facility in genetic testing, this test utilizes advanced molecular techniques to detect the presence of the ZBTB16-RARA fusion gene. The cost of the test is 4400 AED, reflecting the comprehensive analysis and the specialized technology employed to achieve precise results. Identifying the genetic underpinnings of acute promyelocytic leukemia through this test is pivotal for implementing effective treatment plans, including the potential use of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), which have shown significant success in patients with specific genetic mutations.
Given the complexity and the life-threatening nature of leukemia, the ZBTB16 Gene Leukemia Acute Promyelocytic PLZF/RARA Type Genetic Test represents a crucial step forward in personalized medicine, offering hope for improved outcomes through targeted therapy.
The PTPN11 gene plays a crucial role in cell signaling and is implicated in various cellular processes including cell growth and differentiation. Mutations in the PTPN11 gene are closely associated with juvenile myelomonocytic leukemia (JMML), a rare and aggressive form of childhood leukemia characterized by the overproduction of myelomonocytic cells. To diagnose this condition accurately, genetic testing for mutations in the PTPN11 gene is essential.
DNA Labs UAE offers a specialized genetic test aimed at detecting mutations in the PTPN11 gene to confirm a diagnosis of juvenile myelomonocytic leukemia. This test is a vital tool for healthcare professionals in the diagnosis and management of JMML, enabling them to tailor treatment strategies according to the genetic makeup of the leukemia. The cost of the PTPN11 gene leukemia juvenile myelomonocytic genetic test is 4400 AED. Conducted in state-of-the-art facilities, this test offers families and their healthcare providers critical insights into the condition, facilitating informed decisions regarding treatment options and management plans.
The NCF1 gene is implicated in a condition known as Granulomatous Disease, specifically the Chronic Granulomatous Disease (CGD) of the Autosomal Recessive Cytochrome b-Positive Type 1. This rare genetic disorder affects the immune system, leading to severe and recurrent infections due to the inability of phagocytes to effectively kill certain bacteria and fungi. The NCF1 gene encodes a component of the NADPH oxidase complex, which is crucial for producing reactive oxygen species used by phagocytes to destroy pathogens.
To diagnose this specific type of CGD, a genetic test targeting the NCF1 gene can be conducted. This test is crucial for confirming the diagnosis, understanding the disease's severity, and guiding treatment decisions. It involves analyzing the patient's DNA to identify mutations in the NCF1 gene that are responsible for the condition.
In the United Arab Emirates, this specific genetic test is available at DNA Labs UAE. The test is priced at 4400 AED. Opting for this test at DNA Labs UAE ensures that individuals suspected of having this form of CGD can receive a definitive diagnosis, which is essential for the effective management of the condition and to inform family planning decisions.
The "ANTXR1 Gene Hemangioma Capillary Infantile Genetic Test" is a specialized diagnostic procedure aimed at identifying mutations in the ANTXR1 gene, which are associated with the development of infantile capillary hemangiomas. These are benign vascular tumors that usually appear in early childhood and can cause various complications depending on their size and location. The test involves analyzing the patient's DNA to detect any genetic anomalies linked to this condition, offering crucial information for early diagnosis and management.
Performed at DNA Labs UAE, a leading facility in genetic testing, this test is priced at 4400 AED. The laboratory utilizes advanced genomic technologies to ensure accurate and reliable results, aiding in the formulation of targeted treatment plans. This test is particularly valuable for families with a history of capillary hemangiomas, as it can help in predicting the likelihood of occurrence in infants, facilitating early interventions that can significantly improve outcomes.
